Now showing items 1-2 of 2
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
(Drug and alcohol dependence, 2014-05)
The approval of extended release injectable naltrexone (XR-NTX; Vivitrol(®)) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. ...
Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study.
(Journal of psychiatric research, 2014-03)
The racial/ethnic composition of the US population is shifting, with the nonwhite population growing faster than whites. We examined cannabis use disorder (CUD) prevalences and correlates in seven racial/ethnic groups. We ...